ALK Rearrangement Adenocarcinoma with Histological Transformation to S | OTT – Dove Medical Press

Posted: February 19, 2020 at 12:45 am

Taisuke Kaiho,1 Takahiro Nakajima,1 Shunichiro Iwasawa,2 Yoko Yonemori,3 Ichiro Yoshino1

1Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan; 2Department of Respirology, Chiba University Graduate School of Medicine, Chiba, Japan; 3Department of Pathology, Chiba Rosai Hospital, Chiba, Japan

Correspondence: Takahiro NakajimaDepartment of General Thoracic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanTel +81-43-222-7171Fax +81-43-226-2172Email takahiro_nakajima@med.miyazaki-u.ac.jp

Abstract: Specific tyrosine-kinase inhibitors (TKIs) are widely used for the treatment of non-small-cell lung cancers with anaplastic lymphoma kinase (ALK) translocations. However, most treated patients eventually develop resistance to the TKIs. The histological transformation into small cell carcinoma is well known to be the underlying mechanism for acquired resistance; however, transformation to squamous cell carcinoma is extremely rare. We, herein, report a case of ALK rearrangement-positive adenocarcinoma that transformed to squamous cell carcinoma after administration of alectinib, and was found to be resistant to ceritinib.

Keywords: lung adenocarcinoma, anaplastic lymphoma kinase, transformation, squamous cell carcinoma, acquired resistance

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
ALK Rearrangement Adenocarcinoma with Histological Transformation to S | OTT - Dove Medical Press

Related Posts